Literature DB >> 27521776

Cerebral microvascular blood flow and CO2 reactivity in pulmonary arterial hypertension.

Erika Treptow1, Mayron F Oliveira2, Aline Soares2, Roberta P Ramos1, Luiz Medina2, Rita Lima2, Maria Clara Alencar2, Eloara Vieira Ferreira1, Jaquelina S Ota-Arakaki3, Sergio Tufik4, Luiz E Nery2, Lia Rita Bittencourt4, J Alberto Neder5.   

Abstract

Hypocapnia and endothelial dysfunction might impair microvascular cerebral blood flow (CBFmicr) and cerebrovascular reactivity to CO2 (CVRCO2). Pulmonary arterial hypertension (PAH) is characteristically associated with chronic alveolar hyperventilation and microvascular endothelial dysfunction. We therefore determined CBFmicr (pre-frontal blood flow index (BFI) by the indocyanine green-near infrared spectroscopy methodology) during hypocapnia and hypercapnia in 25 PAH patients and 10 gender- and age-matched controls. Cerebral BFI was lower in patients than controls at similar transcutaneous PCO2 (PtcCO2) levels in both testing conditions. In fact, while BFI increased from hypocapnia to hypercapnia in all controls, it failed to increase in 17/25 (68%) patients. Thus, BFI increased to a lesser extent from hypo to hypercapnia ("Δ") in patients, i.e., they showed lower Δ BFI/Δ PtcCO2 ratios than controls. In conclusion, CBFmicr and CVRCO2 are lessened in clinically stable, mildly-impaired patients with PAH. These abnormalities might be associated with relevant clinical outcomes (hyperventilation and dyspnea, cognition, cerebrovascular disease) being potentially amenable to pharmacological treatment.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carbon dioxide; Cerebral blood flow; Near-infrared spectroscopy; Pulmonary hypertension; Ventilation

Mesh:

Substances:

Year:  2016        PMID: 27521776     DOI: 10.1016/j.resp.2016.08.001

Source DB:  PubMed          Journal:  Respir Physiol Neurobiol        ISSN: 1569-9048            Impact factor:   1.931


  5 in total

Review 1.  Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Authors:  Nils P Nickel; Ke Yuan; Peter Dorfmuller; Steeve Provencher; Yen-Chun Lai; Sebastien Bonnet; Eric D Austin; Carl D Koch; Alison Morris; Frédéric Perros; David Montani; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

2.  Brain Structural Changes in Patients with Pulmonary Arterial Hypertension.

Authors:  Bhaswati Roy; Susana Vacas; Luke Ehlert; Kathy McCloy; Rajan Saggar; Rajesh Kumar
Journal:  J Neuroimaging       Date:  2021-02-09       Impact factor: 2.486

3.  Compromised Cerebrovascular Regulation and Cerebral Oxygenation in Pulmonary Arterial Hypertension.

Authors:  Simon Malenfant; Patrice Brassard; Myriam Paquette; Olivier Le Blanc; Audrey Chouinard; Valérie Nadeau; Philip D Allan; Yu-Chieh Tzeng; Sébastien Simard; Sébastien Bonnet; Steeve Provencher
Journal:  J Am Heart Assoc       Date:  2017-10-12       Impact factor: 5.501

4.  Continuous reduction in cerebral oxygenation during endurance exercise in patients with pulmonary arterial hypertension.

Authors:  Simon Malenfant; Patrice Brassard; Myriam Paquette; Olivier Le Blanc; Audrey Chouinard; Sébastien Bonnet; Steeve Provencher
Journal:  Physiol Rep       Date:  2020-03

5.  Nocturnal hypercapnia with daytime normocapnia in patients with advanced pulmonary arterial hypertension awaiting lung transplantation.

Authors:  Yoshinari Nakatsuka; Toyofumi Chen-Yoshikawa; Hideyuki Kinoshita; Akihiro Aoyama; Hiroyasu Kubo; Kimihiko Murase; Satoshi Hamada; Hirofumi Takeyama; Takuma Minami; Naomi Takahashi; Kiminobu Tanizawa; Tomohiro Handa; Toyohiro Hirai; Hiroshi Date; Kazuo Chin
Journal:  PLoS One       Date:  2020-04-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.